Consolidated Portfolio Review Corp Has $316,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Consolidated Portfolio Review Corp decreased its position in Pfizer Inc. (NYSE:PFE) by 17.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 10,970 shares of the biopharmaceutical company’s stock after selling 2,263 shares during the period. Consolidated Portfolio Review Corp’s holdings in Pfizer were worth $316,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Worth Asset Management LLC bought a new position in shares of Pfizer during the 1st quarter valued at about $29,000. Briaud Financial Planning Inc acquired a new position in shares of Pfizer in the third quarter valued at approximately $30,000. GoalVest Advisory LLC increased its position in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. acquired a new stake in shares of Pfizer during the third quarter worth $34,000. Finally, VisionPoint Advisory Group LLC lifted its holdings in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Guggenheim started coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, April 1st. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Stock Down 1.8 %

Pfizer stock opened at $25.86 on Monday. The company’s 50-day moving average price is $27.28 and its two-hundred day moving average price is $28.88. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock has a market cap of $146.43 billion, a P/E ratio of 71.83, a P/E/G ratio of 1.16 and a beta of 0.61. Pfizer Inc. has a twelve month low of $25.61 and a twelve month high of $41.71.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.14 earnings per share. As a group, analysts expect that Pfizer Inc. will post 2.22 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.